You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer
|
|---|---|
| Published in |
BMC Cancer, November 2014
|
| DOI | 10.1186/1471-2407-14-820 |
| Pubmed ID | |
| Authors |
Xichun Hu, Jun Cao, Wenwei Hu, Changping Wu, Yueyin Pan, Li Cai, Zhongsheng Tong, Shusen Wang, Jin Li, Zhonghua Wang, Biyun Wang, Xiaoyu Chen, Hao Yu |
| Abstract |
Apatinib is a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2(VEGFR-2). This study was conducted to assess the efficacy and safety of apatinib in patients with non-triple-negative metastatic breast cancer who had received prior chemotherapy for their metastatic disease. |
Mendeley readers
The data shown below were compiled from readership statistics for 72 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 72 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 11 | 15% |
| Student > Ph. D. Student | 8 | 11% |
| Student > Doctoral Student | 7 | 10% |
| Student > Master | 7 | 10% |
| Professor | 4 | 6% |
| Other | 13 | 18% |
| Unknown | 22 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 15% |
| Nursing and Health Professions | 9 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 7% |
| Agricultural and Biological Sciences | 5 | 7% |
| Economics, Econometrics and Finance | 5 | 7% |
| Other | 11 | 15% |
| Unknown | 26 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 May 2016.
All research outputs
#4,167,289
of 22,769,322 outputs
Outputs from BMC Cancer
#1,001
of 8,280 outputs
Outputs of similar age
#49,233
of 262,838 outputs
Outputs of similar age from BMC Cancer
#30
of 208 outputs
Altmetric has tracked 22,769,322 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,280 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 262,838 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 208 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.